The Trump administration has made a significant move to reclassify marijuana, shifting it from schedule I to schedule III under the Controlled Substances Act, more than four months after an executive order was signed instructing the attorney general to do so.
Marijuana’s schedule I categorization placed it next to substances like heroin, LSD, MDMA, and synthetic opioids. Moving it to schedule III now puts it in the same category as ketamine, anabolic steroids, and testosterone.
Acting attorney general Todd Blanche, appointed by Trump, signed the order and stated that the Department of Justice was fulfilling the president’s pledge to enhance American healthcare. Blanche emphasized the importance of this decision in enabling more profound research into marijuana’s safety and efficacy, widening patient access to treatments, and aiding doctors in making better-informed healthcare choices.
The reclassification comes shortly after another executive order signed by Trump, which accelerates the review process of psychedelic drugs like ibogaine, known for its presence in a west African shrub’s root bark. This move towards easing restrictions and promoting medical research on psychedelic compounds aligns with the administration’s efforts to advance drug policy reforms.
Trump has expressed frustration with the slow progress in rescheduling marijuana during the recent signing of the psychedelic drug order, urging officials to expedite the process. However, the reclassification does not equate to immediate legalization, nor does it impact individuals currently imprisoned for marijuana possession. Business banking restrictions and federal regulations pose ongoing challenges despite the evolving legal landscape across various U.S. states.
It is essential to note that while the reclassification may not permit interstate transportation of schedule III drugs without authorization, it marks a significant development in federal drug policy. With marijuana legalization gaining momentum in several states, there has been an oversupply of the drug, resulting in a decline in wholesale prices, also known as the “ganja glut.”
Republican operative Roger Stone emphasized the significance of marijuana reclassification before the upcoming midterm elections, citing its appeal to young and libertarian voters. Stone accused certain administration officials of impeding the reclassification process, highlighting the complex dynamics surrounding drug policy reforms at the national level.
The recent announcement coincides with changes in key positions within the administration, including the replacement of former attorney general Pam Bondi, who opposed marijuana reform during her tenure in Florida. Blanche’s commitment to engaging with relevant stakeholders, including the Drug Enforcement Administration, underscores the meticulous approach taken towards drug scheduling decisions.
Public opinion on marijuana reform remains divided, with a majority of Americans supporting relaxed restrictions, as indicated by various polls and surveys. Despite evolving attitudes towards marijuana, the executive order’s support reflects a diverse range of perspectives within the American population, underscoring the complex and multifaceted nature of drug policy debates in contemporary society.
